newsfilter
← Latest News
GlobeNewswire·

Bicara Therapeutics to Report Second Quarter 2026 Financial Results and Business Updates on August 11, 2026, at 8:30 AM ET

  • Bicara Therapeutics Inc. (NASDAQ: BCAX) will report second quarter 2026 financial results & business updates before the market opens on Tuesday, August 11, 2026.
  • The company will host a conference call at 8:30 a.m. ET on August 11, 2026, for dial-in access & a live webcast available via its Investors page.
  • Bicara is a clinical-stage biopharmaceutical company focused on bifunctional therapies for solid tumors, utilizing a platform to precisely target tumors & deliver payloads.
  • The lead program, ficerafusp alfa (formerly BCA101), is a bifunctional EGFR-directed monoclonal antibody bound to a human TGF-β ligand trap.
  • Ficerafusp alfa aims to block EGFR-driven survival & proliferation while inhibiting immunosuppressive TGF-β signaling in the tumor microenvironment to improve outcomes & reduce adverse effects.
  • Development of ficerafusp alfa is ongoing in head and neck squamous cell carcinoma & other solid tumor types.
  • Investor inquiries should be directed to Rachel Frank at IR@bicara.com, while media inquiries should contact Tim Palmer at tim.palmer@bicara.com.